Reneuron Share Discussion Threads

[rayrac] 12/7/2016 13:42

Any of you guys in TRX? Looks v promising.

I hold those and these.

[hlp_4u] 12/7/2016 12:37

Fred....there she blows as predicted....next stop 3.5p...GLA

[richtea1701] 12/7/2016 12:25

Interesting

[fredd1eboy] 08/7/2016 15:57

I'll look forward to onwards and upwards hlp. It's about time. Hope you are right. Best wishes. Fred

[hlp_4u] 08/7/2016 15:27

Looks like price has been moved today to trigger all stop losses just below 2.5. Should be onwards and upwards as all the weak holders have gone. Only negative factor will be if open ended funds holding stock are facing excessive redemptions making them forced sellers.

[fredd1eboy] 08/7/2016 11:48

hip. I'm sorry but you do appear a bit misinformed. Woodford made it very clear that his investment in Reneuron was long term, it is reflected in its sheer size. He will, of course, be making money out of the share price drift. Not a lot but making money. Are you trying to make money on a drop. Best of luck to you but I'm staying put, awaiting news over the next 6 months. Best wishes Freddie

[hlp_4u] 08/7/2016 10:59

Remember if Woodfords investors are withdrawing funds....and I think they are he is a forced seller and getting back 90% of your original investment when you you are showing a loss of 55% and being forced to sell suddenly looks mighty attractive to a fund manager.....it is the perennial problem of short termism....RENE should really be a private co...and beware the directors might do that to protect the research and IP from unwanted pillagers. So at this price a lower a no risk buy... but be prepared for it to delist for 5 years if the market slumps...and it will DYORvGLA

[hlp_4u] 08/7/2016 10:49

FredThe co is worth 5p a share to any body who wants the £60m....you make a paper offer at 4p from your cash strapped business, close down sell off the bio staff /IP....and hey presto you have 40 to 50 million in your bank account....that would be bad for stem cell research but commercial sense for a company that has highly rated paper but needs a lot of cash and knows that a placing would slash the value of the paper.....a good old bit ofHanson asset stripping if you go back that far

[fredd1eboy] 08/7/2016 10:06

hip. The asset is intellectual property. At a bid of 4.5p the cost would be prohibitive and an aggressive takeover would not create intellectual value upside as its the brains of those driving the company forward adding the value.
Also as 50% of the company is owned by a handful who invested 5p per share 12 months ago I think your suggestion infeasible.
Best wishes and good to have posts/ideas, keep em coming.
Anyway we are funded for at least 2 years making us pretty unique in the bio industry so provided Rene keep adding value all is good on the investor front
Best wishes.
Freddie

[hlp_4u] 08/7/2016 08:54

Results show progress as per business plan approx 60 million cash even with 2.5m burn per month makes current mkt value look a bit silly.....any co wanting 10 to15m would be better of making a 4.5p bid for RENE to asset strip it rather than have a placing

[fredd1eboy] 07/7/2016 11:50

I did pick up during the presentation...that Ren001 stem cell therapy appears to be long term effective as against Gene Cell therapy which isn't.
Views anyone?

[dickbush] 07/7/2016 09:40

Further, we have appointed local representatives to assist ReNeuron in taking advantage of the recently enacted and favourable regulatory regime for cell therapy candidates in Japan. These new Japanese regulations offer the potential for conditional marketing approval for cell therapies at an earlier stage of clinical development than in the West. We intend to pursue discussions with the Japanese regulatory authorities over the coming months, in order to advance our CTX cell therapy candidate for stroke disability in Japan under the new regulations.

Japan is trying to make itself a leader in biotech.

[fredd1eboy] 07/7/2016 08:21

Years of research to date is valued by the market at £20m. This is what the efforts of a leading uk biotechnology company with £60m is valued at in today's market. When "doubting Thomas" sees the research results for Ren009/003 trials later this year methinks a realistic valuation will quickly follow. In the meantime we are well funded and work can continue without fear of financial wipe out resulting from futile fundraising risk.

[fredd1eboy] 07/7/2016 07:36

How many small bios can make this statement, made earlier today:

"a very robust balance sheet with which to pursue the above programmes through to key clinical milestones over the next two to three years."

[johnb5] 07/7/2016 07:32

No surprises, all therapy trials progressing well and cash being controlled. Will I buy more based on this update. Yes I probably will.

[fredd1eboy] 07/7/2016 07:23

7 July 2016
AIM: RENE
ReNeuron Group plc
("ReNeuron" or "the Company")

Preliminary Results for the Year Ended 31 March 2016

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its preliminary results for the year ended 31 March 2016.

Highlights in the period

· CTX cell therapy candidate for motor disability as a result of stroke:
- Phase II clinical trial - recruitment completed, data expected in Q4 2016
- Pivotal Phase II/III clinical trial planned to commence in H1 2017

· hRPC cell therapy candidate for retinitis pigmentosa:
- Phase I/II clinical trial underway - ReNeuron's first US clinical study
- Pivotal Phase II/III clinical trial planned to commence in 2018

· CTX cell therapy candidate for critical limb ischaemia:
- Phase I clinical trial ongoing - data expected in H2 2016
- Phase II clinical trial planned to commence in H1 2017

· Exosome nanomedicine platform:
- Promising early pre-clinical data in cancer
- Glioblastoma multiforme selected as first clinical target

· Placing completed in August 2015 to raise £68.4 million, before expenses, funding all therapeutic programmes into mid or late-stage clinical development

· Loss for the period of £11.35 million (2015: loss of £8.91 million); cash outflow from operations of £11.92 million (2015: outflow of £8.25 million); cash, cash equivalents and bank deposits at 31 March 2016 of £65.71 million (2015: £12.38 million)

Commenting on the results, Olav Hellebø, ReNeuron's CEO, said:

"Our last financial year was one of significant progress. During the period, we commenced our first clinical trial in the US, a Phase I/II clinical trial of our hRPC cell therapy candidate for retinitis pigmentosa. We have also made progress with our ongoing clinical trials in stroke disability and critical limb ischaemia and we look forward to reporting data from these studies later this year. We have recently selected brain cancer as the first clinical target for our exosome nanomedicine platform, based on exciting pre-clinical data published during the period. Finally, the substantial £68.4 million fundraising completed in the period has provided us with a very robust balance sheet with which to pursue the above programmes through to key clinical milestones over the next two to three years."

Analyst meeting and webcast

A meeting for analysts will be held at 10.00am today at the offices of Buchanan, 107 Cheapside, London, EC2V 6DN.

For a webcast of the analyst presentation, please log on to the following web address about 10 minutes before 10.00am:
hxxp://vm.buchanan.uk.com/2016/reneuron070716/registration.htm

For further details please contact Buchanan on 020 7466 5000.

A recording of the presentation will be made available on ReNeuron's and Buchanan's websites, www.reneuron.com and www.buchanan.uk.com.

[fredd1eboy] 06/7/2016 14:59

Wish it was master. Wish it was

[yachtmaster2] 06/7/2016 13:31

Yours fredd1

[fredd1eboy] 06/7/2016 12:05

Time........Price..........Volume...........Value
10:15:31....2.,725.......1.832,990.........£49.95k

[ps0u3165] 06/7/2016 11:47

Invoke Article 50 of The Lisbon Treaty immediately.

[fredd1eboy] 05/7/2016 19:10

Good post hip. I am surprised it was only 28m. Out of interest have you been monitoring or is there a source on line for this kind of info.
28m/3100m = 1% approx so not necessarily notifiable.
Anyway thanks for that, really usefuland as you state RNS possible by friday.
Best wishes. Freddie

[hlp_4u] 05/7/2016 18:56

Well 28 million shares cleared at 2.35 so that explains the weak price over the last few days....did the holders know something or was Woodfords fund facing large redemptions making it a forced seller...the results or RNS by Friday should make things clearer.

[bigspuds] 04/7/2016 20:16

Find out on Thursday lol.

[fredd1eboy] 04/7/2016 19:34

Well you were right Rocket fuel in that we are are still going down and I stand corrected. I just hope you dont work in Reneurons finance department and that your 2p was too low.
Looking forward to a uplifting post from you in due course.
Best wishes. Freddie